menu
    • menu

    Company profile for Rhizen Pharmaceuticals

    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Rhizen is a clinical-stage biopharmaceutical company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases and metabolic disorders. Rhizen’s proprietary IP in these areas is aimed at generating first-best-early in class, compounds that are expected to offer novel therapeutic options for ...
    Rhizen is a clinical-stage biopharmaceutical company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases and metabolic disorders. Rhizen’s proprietary IP in these areas is aimed at generating first-best-early in class, compounds that are expected to offer novel therapeutic options for these significant unmet medical needs. Rhizen operates as a virtual company leveraging the best efficiencies through out sourcing to globally reputed laboratories.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Rhizen PharmaceuticalsSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Fritz-Courvoisier 40, CH-2300 La Chaux-de-Fonds
    Telephone
    Telephone
    +41 32 580 0113
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://rhizen.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rhizen Announces Data Presentations at ESMO 2022 for Its Clinical Stage Assets
    Rhizen Announces Data Presentations at ESMO 2022 for Its Clinical Stage Assets

    09 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220909005131/en

    BUSINESSWIRE
    09 Sep 2022
    Share Share
    Rhizen Pharma Presents Data on Differentiated PARP and DHODH Inhibitor Programs
    Rhizen Pharma Presents Data on Differentiated PARP and DHODH Inhibitor Programs

    11 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220409005006/en

    BUSINESSWIRE
    11 Apr 2022
    Share Share
    Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase I/Ib
    Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase I/Ib

    01 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211101005515/en/Rhizen-Pharmaceuticals-AG-Announces-First-Patient-Dosing-in-a-Phase-IIb-Study-of-Its-Novel-PARP-Inhibitor-RP12146-in-Patients-With-Advanced-Solid-Tumors

    BUSINESSWIRE
    01 Nov 2021
    Share Share
    Rhizen Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530)
    Rhizen Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530)

    13 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211013005802/en/Rhizen-Pharmaceuticals-AG-Announces-First-Patient-Dosing-in-a-Phase-II-Study-of-Tenalisib-RP6530-in-Locally-Advanced-or-Metastatic-Breast-Cancer-Patients

    BUSINESSWIRE
    13 Oct 2021
    Share Share
    Rhizen Begins Dosing in Phase II Study of Tenalisib in Breast Cancer
    Rhizen Begins Dosing in Phase II Study of Tenalisib in Breast Cancer

    13 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211013005802/en/Rhizen-Pharmaceuticals-AG-Announces-First-Patient-Dosing-in-a-Phase-II-Study-of-Tenalisib-RP6530-in-Locally-Advanced-or-Metastatic-Breast-Cancer-Patients

    BUSINESSWIRE
    13 Oct 2021
    Share Share
    Rhizen doses first subject in Phase II Covid-19 oral drug trial in India
    Rhizen doses first subject in Phase II Covid-19 oral drug trial in India

    22 Sep 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/rhizen-oral-drug-trial-india/

    CLINICALTRIALSARENA
    22 Sep 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search